United States Patent 11,491,176: Scope, Claims, and Patent Landscape (GA, Pegylated Anti-C5 Aptamer)
US Patent 11,491,176 claims a method of treating geographic atrophy (GA) by administering a pegylated aptamer to an eye, where the aptamer is defined by a specific nucleotide sequence (SEQ ID NO: 26) and is an anti-C5 agent. The operative scope is anchored on three pillars: (i) clinical endpoint (reduction in GA lesion growth), (ii) molecular identity (pegylated aptamer with the stated modified nucleotides and inverted deoxythymidine marker), and (iii) dosing and schedule (intravitreal/periocular dosing at defined mg-per-eye ranges on biweekly, monthly, or quarterly schedules).
What does the patent claim, in plain operational terms?
The independent claim (Claim 1) covers a treatment regimen rather than the aptamer product as such. It is structured as:
1) Indication
- Treat geographic atrophy in a human subject in need thereof.
2) Act
- Administer to the eye a pegylated aptamer.
- Dosage range: 0.3 mg/eye to 5 mg/eye.
- Dosing frequency: biweekly, monthly, or quarterly.
3) Drug identity
- The aptamer comprises SEQ ID NO: 26 with specified chemical modifications:
- fC and fU = 2’-fluoro nucleotides
- mG and mA = 2’-OMe nucleotides
- all other nucleotides = 2’-OH
- 3T indicates an inverted deoxythymidine
- aptamer is provided as a salt if needed
- The aptamer is an anti-C5 agent.
- The pegylated aptamer is explicitly required in the claim.
4) Outcome
- Administration reduces growth of a lesion associated with GA.
This combination makes Claim 1 a targeted claim that is difficult to design around without either changing the aptamer identity or changing the therapy mechanics in a way that removes coverage.
What is the claim architecture and how broad is it?
Independent claim scope
Claim 1 defines the “core” coverage. The scope is broad on:
- Route: later dependent claims allow intravitreal or periocular (Claim 17), and anterior/posterior chamber (Claim 18).
- Form: later dependent claims list multiple delivery formats (Claim 16).
- Schedule: explicitly accepts biweekly, monthly, quarterly (also narrowed by dependent claims).
- Pegylation concept: later claims add pegylated moiety conjugation and PEG size/structure options, but Claim 1 already requires “pegylated aptamer,” meaning pegylation is mandatory.
Claim 1 is narrow on:
- Molecular identity of the aptamer (requires SEQ ID NO: 26 with the specific modification map and 3T inverted deoxythymidine).
- Antigen target: must be anti-C5.
- Quantified dosing range: 0.3 mg/eye to 5 mg/eye.
- Endpoint: reduction in growth of a GA lesion.
Dependent claim ladder
Dependent claims add specificity that can create multiple “entry points” for design-around attempts (for example, by using different PEG chemistry but still matching sequence, or by changing schedule). The key dependent claims:
The practical effect: even if a competitor matches the aptamer sequence, they still need to avoid the pegylation and regimen constraints to exit the claim boundary.
What does the aptamer definition lock down?
The molecular identity is one of the strongest barriers to competition. Claim 1 requires a pegylated aptamer comprising:
Landscape implication
Because Claim 1 hard-codes the modification scheme and marker, partial substitutions (for example, switching 2’-F to 2’-OMe at a subset, or changing terminal capping chemistry) may evade depending on the claim construction. But as written, the claim appears to require the defined modified-nucleotide pattern and the inverted deoxythymidine marker.
What does “anti-C5” cover and how does it affect scope?
Claim 1 states the aptamer is an anti-C5 agent. This ties the sequence to complement C5 target engagement.
Design-around pressure
A substitute aptamer that targets a different complement component (C3, C5a only, or upstream complement components) can avoid “anti-C5,” even if it is pegylated and used on a GA endpoint. Conversely, if the aptamer retains anti-C5 binding, the sequence limitation remains the main differentiator.
Key dose and schedule constraints (where competitors can attempt to exit coverage)
Independent claim dosing
- 0.3 mg/eye to 5 mg/eye
- Frequencies: biweekly, monthly, quarterly
Dependent dosing refinements
- 0.5 mg to 2 mg/eye (Claim 14)
- about 1 mg/eye (Claim 15)
- Monthly (Claim 10)
- “Monthly for three injections, and the fourth and fifth injections three or four months after third injection” (Claim 11)
- Bimonthly (Claim 12)
- Quarterly (Claim 13)
Outcome benchmark
- at least 10% reduction in GA lesion growth vs non-treated control (Claim 9)
Operational read
Any competitor trying to avoid Claim 1 coverage has only a few strategic levers:
- change dosing to outside the mg/eye range
- change administration frequency to outside the enumerated schedules
- change the drug identity so it no longer fits “pegylated aptamer” comprising SEQ ID NO: 26 with the specified modifications and anti-C5 designation
- change the endpoint such that it no longer claims “reduces growth of lesion associated with GA” (hard in practice, because clinical outcome claims follow biology)
Even when attempting to step outside one dependent claim, Claim 1 still applies if the core conditions are satisfied.
Administration and formulation: where the claim is permissive
The independent claim already requires administration to the eye. Dependent claims widen the practical implementation:
- Route: intravitreal or periocular (Claim 17)
- Compartment: anterior or posterior chamber (Claim 18)
- Form factors (Claim 16): delivery device, implant/intraocular implant, injectable, drops, sprays, gels, creams, aerosols, and controlled release formats (Claim 19)
Landscape implication
This is a formulation-flexible patent. That reduces the value of changing dosage form alone as a design-around. The molecule and regimen still drive infringement risk.
Scope summary table: claim coverage vs specific constraints
| Claim element |
Coverage in Claim 1 |
Additional narrowing in dependent claims |
| Indication |
Geographic atrophy (GA), human |
none |
| Target |
Anti-C5 |
none |
| Drug identity |
“Pegylated aptamer” comprising SEQ ID NO: 26 with defined modifications and 3T inverted deoxythymidine |
none beyond pegylation attachment and PEG structure |
| Dose per eye |
0.3 mg/eye to 5 mg/eye |
0.5–2 mg/eye (C14); about 1 mg/eye (C15) |
| Schedule |
biweekly, monthly, or quarterly |
monthly (C10), bimonthly (C12), quarterly (C13), and a specific multi-injection pattern (C11) |
| Outcome |
reduces growth of GA lesion |
at least 10% reduction (C9) |
| PEG attachment |
pegylated aptamer required |
linker conjugation (C2); 5’ end (C3); branched PEG (C4); MW >10 kDa (C5); about 40 kDa (C6) |
| Route |
eye administration |
intravitreal/periocular (C17); anterior/posterior chamber (C18) |
| Formulation |
not limited in Claim 1 |
extensive list (C16); controlled release (C19) |
Patent landscape map: what this patent likely blocks
Because the claims are method-based with explicit drug identity, the practical “blocked space” is centered on:
1) Pegylated SEQ ID NO: 26 anti-C5 aptamer dosing for GA in humans
2) Conjunctive coverage of dosing ranges and schedule patterns
3) Clinical outcome framing around GA lesion growth reduction
Likely infringement profiles (high risk)
- Competitors using the same SEQ ID NO: 26 anti-C5 aptamer and pegylating it in a manner that still fits “pegylated aptamer” with linker conjugation and the same modified nucleotide pattern.
- Regimens delivering 0.3–5 mg per eye with biweekly/monthly/quarterly dosing while claiming reduction in GA lesion growth.
- Products that modify formulation (implant, gel, controlled release) but keep the same aptamer identity and anti-C5 function.
Likely safer profiles (lower risk)
- Switching to an aptamer that is not SEQ ID NO: 26 or does not include the stated modification pattern and inverted 3T marker.
- Switching target away from C5.
- Using a pegylated anti-C5 agent but with a dosing regimen consistently outside 0.3–5 mg/eye or outside the enumerated schedule (biweekly/monthly/quarterly). However, schedule avoidance must be consistent because multiple frequencies are explicitly allowed in Claim 1.
How to interpret the claim’s “pegylation” boundaries
The claim requires pegylation but then dependent claims detail:
- conjugation via a linker
- at the 5’ end
- branched PEG
- MW constraints including about 40 kDa
Strategic read-through
- If a competitor uses a pegylated version of the same aptamer but with unbranched PEG, or a PEG MW far outside 10 kDa or 40 kDa, they may still fall under Claim 1 because Claim 1 does not include PEG MW or branching requirements. The dependent claims add narrower coverage but do not remove Claim 1’s broader pegylation requirement.
- If a competitor uses a pegylated moiety that is not linked (for example, not conjugated via linker) they still may fit Claim 1’s “pegylated aptamer” depending on claim construction, but Claim 2/3 would likely be evaded.
Key Takeaways
- US 11,491,176 is a GA treatment method claim that is locked to a pegylated anti-C5 aptamer comprising SEQ ID NO: 26 with specific nucleotide modifications (2’-F, 2’-OMe, remaining 2’-OH, and 3T inverted deoxythymidine).
- The core regimen covered by Claim 1 is 0.3–5 mg per eye with biweekly/monthly/quarterly administration, targeting reduced growth of GA lesions.
- Dependent claims broaden operational flexibility on formulation, route, and compartment, while further specifying PEG architecture (branched, 5’ conjugation, MW around 40 kDa), dose points (about 1 mg/eye), and a 10% lesion-growth reduction benchmark.
- For landscape planning, the patent’s enforcement risk concentrates on programs using the same aptamer identity (sequence + modification pattern) and deploying it in C5 anti-activity with dosing schedules within the enumerated ranges. Changing only delivery form or injection device is unlikely to avoid Claim 1.
FAQs
1) Is the patent about the aptamer molecule or the treatment method?
It is drafted primarily as a method of treating geographic atrophy using a pegylated anti-C5 aptamer administered to the eye, with dosing and clinical lesion growth outcomes.
2) What is the strongest design-around barrier?
The aptamer identity: SEQ ID NO: 26 plus the specific modification pattern (2’-fluoro, 2’-OMe, 2’-OH elsewhere) and the 3T inverted deoxythymidine marker, along with the anti-C5 requirement.
3) Does switching to a different formulation (implant vs injection) avoid coverage?
Not by itself. Dependent claims list many forms and also include controlled release. The key constraints remain the pegylated aptamer identity and the dosing regimen in Claim 1.
4) Can avoiding dependent dose targets (like “about 1 mg/eye”) fully remove risk?
No. Those are dependent claim refinements. If the regimen still falls within Claim 1’s 0.3–5 mg/eye and accepted schedules, risk remains.
5) Does the patent require a specific PEG molecular weight to be infringed under Claim 1?
Claim 1 requires a pegylated aptamer, but it does not impose PEG MW or branching. PEG MW and branching requirements sit in dependent claims.
References
No external sources were cited because only the claim text provided was used.
